Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-8046
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HRS-8046 is an innovative, small molecule inhibitor independently developed by Hengrui Pharma for the treatment of solid tumors harboring the KRAS G12D mutation. KRAS G12D is a highly prevalent oncogenic driver mutation frequently found in pancreatic, colorectal, and other solid tumors, historically considered "undruggable". By selectively targeting the KRAS G12D mutant protein, HRS-8046 aims to inhibit downstream oncogenic signaling pathways, thereby suppressing tumor cell proliferation and survival. In October 2026, the National Medical Products Administration (NMPA) of China approved clinical trials for HRS-8046 tablets as a monotherapy in patients with KRAS G12D-mutant solid tumors.
- Other names
- HRS-8046 tabletsHRS8046 tabletsHRS 8046 tabletsHRS-8046片
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on HRS-8046.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-8046.